WHO (WHO) released a report that lists the first-ever fungal "priority pathogens" list, covering the catalog of 19 fungi that pose the greatest threat to public health. The list of fungal priority pathogens (FPPL) for WHO is the first global effort to systematically prioritize fungal pathogens, taking into account unmet research and development (R&D) needs and recognized public health importance. The report is based on research led by the University of Sydney, Australia.
New evidence shows that the incidence and geographical scope of fungal diseases have expanded globally due to global warming and the increase in international travel and trade. During the COVID-19 pandemic, the reported incidence of aggressive fungal infections in hospitalized patients has increased significantly. As fungi that lead to common infections, such as thrush caused by Candida, are increasingly resistant to treatment, the risk of developing a more invasive form of infection in the general population is increasing. "From the shadow of the pandemic of antibiotic resistance, fungal infections are growing, and the resistance to treatments is becoming a public health problem around the world," said Dr. Hanan Balkhy, Assistant Director-General for Antimicrobial Resistance (AMR), WHO. "Three Priority Categories:
Three Priority Categories
WHO's FPPL list is divided into three categories: Critical, High and Moderate Priority.
1) The critical group includes Candida albicans , which is highly resistant and causes multiple outbreaks in hospitals around the world, as well as Cryptococcal neoplasm, Aspergillus fumigatus and Candida albicans.
2) The advanced group includes some other fungi from the Candida albicans family as well as some other fungi such as clots, which contain fungi that cause clots or "black mold", an infection that rises rapidly in severe patients during COVID-19 – especially in India. Some other fungi are listed in the group
3), including Coccidioidae and Cryptococcus Getty.
Fungal infection treatment
WHO says fungal pathogens are a major threat to public health because they are becoming more common and resistant to treatment. Currently, only four types of antifungal drugs are available, and there are few clinical candidates. "We need more data and evidence on fungal infections and antifungal resistance to inform and improve responses," said Dr. Haileyesus Getahun, Director of the Global Coordination Department of WHO AMR. "We need more data and evidence on fungal infections and antifungal resistance to inform and improve responses."
Fungal infection, who is at greater risk?
Invasive forms of fungal infection often affect severely ill patients and those with severe underlying immune system-related diseases. The population with the greatest risk of invasive fungal infection includes cancer patients, HIV/ AIDS patients, organ transplants, chronic respiratory disease patients and patients after primary tuberculosis infection.
download address:
https://www.who.int/publications/i/item/9789240060241
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-